Percutaneous Coronary Intervention (PCI) Market Opportunity
PCI is a non-surgical procedure that utilizes special catheters to access blood vessels in the heart, such as to open blocked arteries. Such procedures include angioplasty and stent replacements, and are performed by a specialized interventional cardiologist. When undergoing PCI procedures, patients are given anticoagulant medications to prevent the formation of potentially dangerous clots. Uncontrolled clotting could result in a stroke, heart attack, or deep vein thrombosis, if the clots lodge in the brain, heart or legs. Treatment with PMX-60056 at the end of the procedure is designed to rapidly restore normal blood clotting. This is expected to reduce the incidence of bleeding and may allow for faster removal of the catheter and thereby potentially shorten the time of the procedure.
In the United States and Europe more than 2 million PCI procedures are performed annually. Major bleeding events can be a side effect of PCI and have been correlated with short and long term mortality. In the United States, a major bleed can result in over $15,000 in additional hospital costs, and can more than triple the length of hospital stay. By reducing the incidence of bleeding, catheter removal time, and time to patient ambulation, PMX-60056 may improve the safety and efficacy clinical outcomes of the PCI procedure while providing pharmacoeconomic advantages.